Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-08-03
Target enrollment:
Participant gender:
Summary
This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab
combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed
after immune checkpoint inhibitors.